<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Collapsing focal segmental glomerulosclerosis (collapsing glomerulopathy)
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gerald B Appel, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            J Ashley Jefferson, MD, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Brad H Rovin, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H458456078">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Collapsing focal segmental glomerulosclerosis (collapsing FSGS; also known as collapsing glomerulopathy) is a pattern of kidney injury characterized by segmentally or globally collapsed and sclerotic glomerular capillaries, with hyperplasia and hypertrophy of overlying glomerular epithelial cells. Patients typically present with the nephrotic syndrome. In the setting of active HIV infection, the kidney disease is also called "HIV-associated nephropathy" (HIVAN); however, collapsing FSGS is now increasingly described in patients without HIV, many of whom carry an underlying high-risk apolipoprotein L1 (
         <em>
          APOL1
         </em>
         ) genotype. Collapsing FSGS is best considered as a histopathologic diagnosis associated with a heterogeneous group of disorders.
        </p>
        <p>
         Collapsing FSGS not associated with HIV infection will be reviewed here. Collapsing FSGS and other kidney diseases that occur in association with HIV infection are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14027.html" rel="external">
          "Overview of kidney disease in patients with HIV"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The epidemiology, classification, pathogenesis, clinical features, diagnosis, and treatment of other forms of FSGS are discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">
          "Focal segmental glomerulosclerosis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">
          "Focal segmental glomerulosclerosis: Pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">
          "Focal segmental glomerulosclerosis: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4061732201">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of collapsing FSGS not associated with HIV infection is unclear and varies among different countries [
         <a href="#rid1">
          1
         </a>
         ]. However, collapsing FSGS appears to comprise an increasing proportion of all cases of idiopathic FSGS (10 to 24 percent in some older series) [
         <a href="#rid2">
          2
         </a>
         ]. In one report, collapsing FSGS represented 1.4 percent of all kidney biopsies performed at a single large center over a 15 year period [
         <a href="#rid3">
          3
         </a>
         ]. Both sexes are equally affected, and most, but not all, reports have noted a predominance of Black patients [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H780618844">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of collapsing FSGS in patients not infected with HIV is not clear [
         <a href="#rid4">
          4
         </a>
         ]. As with HIV-associated nephropathy (HIVAN), the underlying pathogenic event appears to be a severe insult to the integrity and biology of the glomerular visceral (podocytes) and parietal epithelial cells [
         <a href="#rid2">
          2,4
         </a>
         ]. The overlying hyperplastic epithelial cells lack normal podocyte markers, which has been attributed to podocyte dedifferentiation and proliferation; however, many of these cells express markers that are consistent with a parietal epithelial cell origin [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2575847808">
         <span class="h2">
          Genetic factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic susceptibility may contribute to the pathogenesis of collapsing FSGS.
        </p>
        <p class="headingAnchor" id="H165368138">
         <span class="h3">
          <i>
           APOL1
          </i>
          high-risk alleles
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is a predominance of Black patients noted in most reports of idiopathic collapsing FSGS [
         <a href="#rid2">
          2-4
         </a>
         ]. Two high-risk allelic variants (G1, G2) in the gene encoding apolipoprotein L1 (
         <em>
          APOL1
         </em>
         ) are common in individuals of West African ancestry and have been associated with protection from trypanosomal sleeping sickness. The presence of two high-risk alleles for
         <em>
          APOL1
         </em>
         (G1G1, G1G2, or G2G2) is associated with an increased risk of nondiabetic kidney disease, hypertension in Black patients, and focal segmental glomerulosclerosis [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117559.html" rel="external">
          "Focal segmental glomerulosclerosis: Genetic causes", section on 'FSGS in Black patients'
         </a>
         .)
        </p>
        <p>
         In collapsing FSGS, these high-risk variants are strongly overrepresented in patients with HIVAN [
         <a href="#rid7">
          7
         </a>
         ] as well as those with idiopathic collapsing FSGS [
         <a href="#rid7">
          7,8
         </a>
         ] and collapsing FSGS associated with systemic lupus erythematosus [
         <a href="#rid9">
          9
         </a>
         ], interferon therapy [
         <a href="#rid10">
          10
         </a>
         ], membranous nephropathy [
         <a href="#rid11">
          11
         </a>
         ], kidney transplantation [
         <a href="#rid12">
          12
         </a>
         ], and coronavirus disease 2019 (COVID-19) infection [
         <a href="#rid13">
          13-16
         </a>
         ] (see
         <a class="local">
          'Infections'
         </a>
         below). Mechanisms by which these high-risk variants lead to glomerular and podocyte injury are being actively investigated but include disruption of lysosomal or plasma membranes, insertion of pores or ion channels into podocyte cell membranes, and creation of a proinflammatory milieu leading to cell damage [
         <a href="#rid17">
          17-20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H475957987">
         <span class="h3">
          Other susceptibility genes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genes that encode proteins directly involved in mitochondrial function have been associated with collapsing FSGS [
         <a href="#rid4">
          4
         </a>
         ]. As an example, primary coenzyme Q10 deficiency secondary to genetic defects in the
         <em>
          COQ2
         </em>
         gene or
         <em>
          PDSS2
         </em>
         gene is a cause of collapsing FSGS [
         <a href="#rid21">
          21,22
         </a>
         ]. This suggests that some disorders associated with collapsing FSGS may induce disease by affecting mitochondrial function, an important pathway leading to cell death, in kidney parenchyma. (See
         <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">
          "Mitochondrial myopathies: Clinical features and diagnosis", section on 'Coenzyme Q10 deficiency'
         </a>
         .)
        </p>
        <p>
         Other genetic diseases associated with collapsing FSGS include action myoclonus-renal failure syndrome (
         <em>
          SCARB2
         </em>
         defect) [
         <a href="#rid23">
          23
         </a>
         ], Charcot-Marie-Tooth disease (
         <em>
          INF2
         </em>
         defect) [
         <a href="#rid24">
          24
         </a>
         ], Schimke dysplasia (
         <em>
          SMARCAL1
         </em>
         defect) [
         <a href="#rid25">
          25
         </a>
         ], mandibular dysplasia (
         <em>
          ZMPSTE24
         </em>
         defect) [
         <a href="#rid26">
          26
         </a>
         ], Galloway-Mowat syndrome (
         <em>
          WDR73
         </em>
         defect) [
         <a href="#rid27">
          27,28
         </a>
         ], and
         <em>
          CDAP2
         </em>
         deficiency.
        </p>
        <p>
         Several kindreds with familial collapsing FSGS have been described [
         <a href="#rid29">
          29
         </a>
         ]. In one kindred, comprised of all White individuals, genetic defects in the
         <em>
          TRPC6
         </em>
         gene were identified, which have also been linked to noncollapsing FSGS. This emphasizes that known genetic forms of FSGS can present with a collapsing pattern distinct from a mechanism related to
         <em>
          APOL1
         </em>
         .
        </p>
        <p class="headingAnchor" id="H2701497850">
         <span class="h2">
          Role of immune activation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Collapsing FSGS has been associated with disorders that alter the activity of the immune system (
         <a class="graphic graphic_table graphicRef72313" href="/z/d/graphic/72313.html" rel="external">
          table 1
         </a>
         ), suggesting that immune activation may play a role in the pathogenesis of this disease [
         <a href="#rid4">
          4
         </a>
         ]. Proinflammatory cytokines (notably type 1 interferons) produced during immune responses upregulate the expression of mutant
         <em>
          APOL1
         </em>
         in glomerular epithelial cells, causing direct injury to these cells [
         <a href="#rid10">
          10
         </a>
         ]. Enhanced interferon signaling pathways and collapsing FSGS have also been described with viral infections (HIV, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), therapeutic interferon (interferon-alpha, -beta, or -gamma), systemic lupus erythematosus, natural killer cell leukemia [
         <a href="#rid30">
          30
         </a>
         ], and rare genetic disorders associated with high interferon levels (eg, stimulator of interferon genes [STING]-associated vasculopathy [
         <a href="#rid31">
          31
         </a>
         ]). Biopsies from these patients may demonstrate endothelial tubuloreticular inclusions as a hallmark of interferon upregulation. (See
         <a class="local">
          'Infections'
         </a>
         below and
         <a class="local">
          'Bisphosphonates and other drugs'
         </a>
         below and
         <a class="local">
          'Autoimmune disorders'
         </a>
         below.)
        </p>
        <p>
         However, the finding of collapsing FSGS in patients with active HIV infection suggests that downregulation of certain parts of the immune system may also contribute to the development of this lesion.
        </p>
        <p class="headingAnchor" id="H1442185022">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of cases of collapsing FSGS are idiopathic. However, collapsing FSGS has been reported to occur in association with a growing list of disorders (
         <a class="graphic graphic_table graphicRef72313" href="/z/d/graphic/72313.html" rel="external">
          table 1
         </a>
         ). In one series of 42 patients, for example, concurrent illnesses were present in 13 (31 percent); these included a systemic lupus erythematosus–like disorder, hepatitis C virus infection, and multiple myeloma [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1196660381">
         <span class="h2">
          Idiopathic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of collapsing FSGS not associated with HIV infection are idiopathic [
         <a href="#rid2">
          2-4
         </a>
         ]. In one series of 88 patients with collapsing FSGS, 77 percent had idiopathic disease [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         The etiology of idiopathic collapsing FSGS is, by definition, unknown. Circulating factors that may be toxic to the glomerular capillary wall or to glomerular visceral epithelial cells have been reported, but not conclusively identified, in patients with collapsing FSGS [
         <a href="#rid4">
          4,33
         </a>
         ]. The recurrence of collapsing FSGS after kidney transplantation also supports the presence of a circulating factor in some of these patients [
         <a href="#rid4">
          4,34,35
         </a>
         ]. However, many patients with collapsing FSGS who receive a kidney allograft do not have recurrence of their disease and the
         <em>
          APOL1
         </em>
         risk alleles from the donor kidney, not the recipient, are associated with recurrence [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">
          "Focal segmental glomerulosclerosis: Pathogenesis", section on 'Putative circulating permeability factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1195571027">
         <span class="h2">
          Infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of infections other than HIV infection have been associated with collapsing FSGS. These include viral, bacterial, and parasitic diseases such as parvovirus B19 infection, pulmonary tuberculosis, cytomegalovirus infection, schistosomiasis, filariasis, falciparum malaria, and SARS-CoV-2 infection (
         <a class="graphic graphic_table graphicRef72313" href="/z/d/graphic/72313.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid13">
          13,14,36-41
         </a>
         ]. Since most infections (excluding parvovirus and COVID-19) are only rarely associated with collapsing FSGS, and since the infections mentioned above have been found with other patterns of FSGS, further studies are needed to better understand these associations. (See
         <a class="local">
          'Role of immune activation'
         </a>
         above.)
        </p>
        <p>
         Collapsing FSGS in patients infected with SARS-CoV-2 has been termed COVID-19-associated nephropathy (COVAN) to distinguish it from most cases of acute kidney injury in patients with COVID-19, which are characterized by acute tubular injury [
         <a href="#rid14">
          14,42-44
         </a>
         ]. In one single center series of 23 patients with COVAN, 16 (70 percent) were male, 21 (91 percent) were Black, and most had only mild or moderate severity of COVID-19 infection [
         <a href="#rid14">
          14
         </a>
         ]. Twenty-two of the 23 patients presented with acute kidney injury (approximately 60 percent required dialysis), 17 had nephrotic range proteinuria, and 6 had the nephrotic syndrome. Among the 17 patients who were genotyped, 16 (94 percent) had two high-risk alleles for
         <em>
          APOL1
         </em>
         . Despite treatment with supportive therapy, antiviral therapy (in 50 percent), or glucocorticoids (in 26 percent), overall outcomes were poor, with only 36 percent of patients achieving a partial remission of proteinuria, 32 percent having no remission, and 32 percent progressing to end-stage kidney disease or death. However, half of the patients who required dialysis were able to discontinue this treatment. Viral infection of the kidney by SARS-CoV-2 was not detected. Similar findings have been reported in other series [
         <a href="#rid43">
          43,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/127552.html" rel="external">
          "COVID-19: Issues related to acute kidney injury, glomerular disease, and hypertension", section on 'COVID-19 associated glomerular disease'
         </a>
         .)
        </p>
        <p>
         One proposed mechanism for COVAN involves infection-stimulated activation of the interferon-chemokine pathway, which upregulates expression of the
         <em>
          APOL1
         </em>
         variant gene, leading to disruption of podocyte autophagy, mitochondrial injury, and promotion of glomerular epithelial cell death [
         <a href="#rid44">
          44
         </a>
         ]. (See
         <a class="local">
          'APOL1 high-risk alleles'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H49816193">
         <span class="h2">
          Bisphosphonates and other drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         An unexpected association has been noted between collapsing FSGS and therapy with the bisphosphonate
         <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">
          pamidronate
         </a>
         in patients with multiple myeloma or breast cancer (given to prevent skeletal complications) who are often treated with high doses [
         <a href="#rid46">
          46-50
         </a>
         ]. A toxic effect on the glomerular epithelial cell is the presumed mechanism.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2801.html" rel="external">
          "Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6663.html" rel="external">
          "Multiple myeloma: The use of osteoclast inhibitors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The initial report described seven such patients who were HIV negative, six of whom had multiple myeloma and had undergone stem cell transplantation, and one of whom had breast cancer without transplantation [
         <a href="#rid47">
          47
         </a>
         ]. A number of additional cases of pamidronate-associated collapsing FSGS have since been reported [
         <a href="#rid48">
          48-50
         </a>
         ]. Almost all those with pamidronate-related collapsing FSGS have been White patients [
         <a href="#rid4">
          4,47-49
         </a>
         ], and most have been older than 55 years of age.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">
          Pamidronate
         </a>
         has also been associated with nephrotic syndrome associated with other glomerular lesions, including noncollapsing FSGS and minimal change disease [
         <a href="#rid46">
          46,49
         </a>
         ]. In some, but not all, reported cases, nephrotic syndrome was reversed when pamidronate was discontinued [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Other bisphosphonates, such as
         <a class="drug drug_general" data-topicid="9427" href="/z/d/drug information/9427.html" rel="external">
          alendronate
         </a>
         and zoledronate, have also been associated with collapsing FSGS in rare cases [
         <a href="#rid46">
          46,52
         </a>
         ].
        </p>
        <p>
         Anabolic steroids and other bodybuilding supplements [
         <a href="#rid53">
          53
         </a>
         ] and the therapeutic use of interferon-alpha, beta, and gamma have all been associated with the development of collapsing FSGS [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">
          "Focal segmental glomerulosclerosis: Pathogenesis", section on 'Anabolic steroids'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">
          "Focal segmental glomerulosclerosis: Pathogenesis", section on 'Interferon'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2918121922">
         <span class="h2">
          Autoimmune disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Collapsing FSGS has been observed in patients with systemic lupus erythematosus [
         <a href="#rid55">
          55-59
         </a>
         ]. As an example, a retrospective review of kidney biopsies performed in patients with SLE over a seven year period revealed 19 HIV-negative patients with collapsing FSGS [
         <a href="#rid55">
          55
         </a>
         ]. Most of those identified were Black patients and were female (17 and 15 patients, respectively); 16 of the 19 patients had symptoms of an active lupus flare at the time of biopsy. All but one patient with available clinical data had nephrotic-range proteinuria (urine protein, 3 to 12 g/day), and all but one had a reduced glomerular filtration rate (GFR; serum creatinine, 1.6 to 26.5 mg/dL [141.4 to 2342.6 micromol/L]). Less than one-half of the patients had concurrent lupus nephritis identified histologically. Follow-up data were available on 13 patients, more than one-half of whom progressed to end-stage kidney disease within two years.
        </p>
        <p>
         Importantly, the development of collapsing FSGS in Black patients with SLE is associated with risk polymorphisms in the
         <em>
          APOL1
         </em>
         gene [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
         Collapsing FSGS has also been associated with other autoimmune conditions including adult-onset Still disease [
         <a href="#rid60">
          60-62
         </a>
         ] and Behçet syndrome [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H711155705">
         <span class="h2">
          IgA nephropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Histopathologic and clinical features of collapsing FSGS have been described in patients with immunoglobulin A (IgA) nephropathy [
         <a href="#rid64">
          64,65
         </a>
         ]. In one study, for example, collapsing FSGS (in the absence of HIV) was identified as an additional finding in the biopsies of 11 out of 128 adults with IgA nephropathy [
         <a href="#rid64">
          64
         </a>
         ]. Compared with other patients in the series, those with histologic features of collapsing FSGS had significantly higher serum creatinine concentrations and significantly more proteinuria at the time of diagnosis, although proteinuria and hypoalbuminemia were less marked than in patients with idiopathic collapsing FSGS. Ten of these 11 patients were followed for a mean of 44 months; nine required dialysis.
        </p>
        <p class="headingAnchor" id="H3090645427">
         <span class="h2">
          Diabetic kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Typical histopathologic and clinical features of collapsing FSGS have also been noted in patients with diabetic kidney disease (DKD). In a study of 534 patients with DKD, 26 HIV-negative patients had collapsing FSGS superimposed on DKD (5 percent) [
         <a href="#rid66">
          66
         </a>
         ]. Those with both lesions had more severe disease at the time of biopsy (the mean serum creatinine was 3.8 mg/dL and mean 24-hour proteinuria was 9.8 grams), and the development of end-stage kidney disease was more rapid than in patients with DKD but without collapsing FSGS.
        </p>
        <p class="headingAnchor" id="H3666958726">
         <span class="h2">
          Thrombotic microangiopathy/acute glomerular ischemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A pathologic pattern consistent with collapsing FSGS has been described in patients with thrombotic microangiopathy (TMA) in native [
         <a href="#rid67">
          67
         </a>
         ] and transplanted [
         <a href="#rid2">
          2,34,68
         </a>
         ] kidneys. In a study of 53 patients with biopsy-proven TMA in the native kidney, collapsing FSGS lesions were identified in 19 (36 percent) [
         <a href="#rid67">
          67
         </a>
         ]. In contrast with patients with idiopathic collapsing FSGS, most of these were White patients, nephrotic syndrome was rare (12 percent), and loss of podocyte immunohistochemical markers was less frequent. Glomerular ischemia and glomerular endothelial injury have been suggested as possible mechanisms. Similarly, glomerular ischemia has been proposed as the mechanism responsible for collapsing FSGS associated with other vaso-occlusive disorders including cholesterol emboli [
         <a href="#rid69">
          69
         </a>
         ], sickle cell anemia [
         <a href="#rid70">
          70
         </a>
         ], DKD [
         <a href="#rid66">
          66
         </a>
         ], and renal infarction [
         <a href="#rid71">
          71
         </a>
         ]. In older patients (age greater than 65 years), this pattern of collapsing FSGS associated with extensive vascular disease and glomerular ischemia is more common [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4228304726">
         <span class="h2">
          Hemophagocytic lymphohistiocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with collapsing FSGS have hemophagocytic lymphohistiocytosis (also known as hemophagocytic syndrome), a nonmalignant activation of bone marrow histiocytes, which phagocytose blood cell precursors [
         <a href="#rid73">
          73,74
         </a>
         ]. This syndrome, which is characterized by high levels of circulating proinflammatory cytokines (ie, cytokine "storm") and serum ferritin (often greater than 3000 mcg/L), can be seen in the setting of infections, autoimmune disease, or lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis"
         </a>
         .)
        </p>
        <p>
         Collapsing FSGS has also been described in adult-onset Still's disease [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1145322494">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with idiopathic collapsing FSGS often present with a similar clinical picture as those with HIV-associated collapsing FSGS. This can include a preceding or ongoing febrile illness (in some patients), severe nephrotic syndrome, kidney function impairment at presentation, and rapid progression to end-stage kidney disease [
         <a href="#rid2">
          2,4,32,75-78
         </a>
         ]. On urinalysis, the nephrotic sediment is associated with heavy proteinuria, lipiduria, and occasionally large granular casts. (See
         <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">
          "HIV-associated nephropathy (HIVAN)", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Compared with typical FSGS, collapsing FSGS presents with more severe kidney involvement, including higher levels of proteinuria (commonly over 10 g/day), profound hypoalbuminemia, and more severe kidney dysfunction [
         <a href="#rid2">
          2,4,79
         </a>
         ]. In one series, for example, the average presenting serum creatinine concentrations of patients with collapsing FSGS were significantly higher than those observed among patients with typical FSGS (3.5 versus 1.3 mg/dL [309 versus 115 micromol/L]) [
         <a href="#rid76">
          76
         </a>
         ]. Similar findings were noted in another report despite a shorter time from presentation to kidney biopsy in the patients with collapsing FSGS [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         In general, kidney ultrasonography of patients with collapsing FSGS shows large echogenic kidneys (even in end-stage kidney disease) as opposed to typical FSGS where smaller, shrunken kidneys are common. (See
         <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">
          "Focal segmental glomerulosclerosis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Clinical features in other secondary forms of collapsing FSGS may be more variable, including a milder phenotype (often sub-nephrotic proteinuria and less severe acute kidney injury [AKI]) in drug-induced and ischemia-associated forms of collapsing FSGS. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H121052920">
         <span class="h1">
          PATHOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         By definition, collapsing FSGS is associated with segmental or global collapse and sclerosis of the glomerular tufts. Most often there is evidence of collapse and sclerosis of the entire glomerular tuft, rather than segmental collapse (
         <a class="graphic graphic_picture graphicRef81601" href="/z/d/graphic/81601.html" rel="external">
          picture 1
         </a>
         ). For many pathologists the finding of collapsing features of even one glomerulus on a kidney biopsy is sufficient for the diagnosis [
         <a href="#rid80">
          80
         </a>
         ]. However, this finding needs to be interpreted within the clinical context of the patient, since a pathological diagnosis of collapsing FSGS from a single glomerulus, in the absence of characteristic clinical features of nephrotic syndrome, may lead to inappropriate treatment. (See
         <a class="local">
          'Diagnosis'
         </a>
         below.)
        </p>
        <p>
         Compared with classic focal FSGS, the following features on kidney biopsy are particularly suggestive of collapsing FSGS:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Marked hypertrophy and hyperplasia of overlying glomerular epithelial cells above the collapsed areas of the tuft [
         <a href="#rid4">
          4,81
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Often severe tubular injury with cystic dilatation of the tubules filled with proteinaceous casts (proliferative microcystic transformation) and tubular degeneration [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The wrinkling and retraction of the glomerular basement membrane [
         <a href="#rid2">
          2,4
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         However, at an advanced stage of the disease, collapsing FSGS cannot always be distinguished histologically from typical FSGS (not otherwise specified).
        </p>
        <p>
         Histologic features that may differ between collapsing FSGS due to HIV from that due to non-HIV infection include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of tubuloreticular structures in glomerular endothelial cells on electron microscopy with HIV-associated disease (
         <a class="graphic graphic_picture graphicRef59839" href="/z/d/graphic/59839.html" rel="external">
          picture 2
         </a>
         ). However, such structures may also be seen in collapsing FSGS associated with other conditions in which interferon signaling pathways are upregulated (eg, viral infections, systemic lupus erythematosus, and interferon therapy). Tubuloreticular lesions may be absent in patients with HIV nephropathy who have been treated with antiretroviral therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A greater incidence of proliferative microcystic transformation with HIV nephropathy [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The proliferation of glomerular epithelial cells in collapsing FSGS may occasionally cause diagnostic confusion with the crescents seen in crescentic glomerulonephritis. The term "pseudocrescents" has often been used in the literature to refer to this finding. Proliferating glomerular epithelial cells are also known to be major constituents of classic crescents [
         <a href="#rid82">
          82
         </a>
         ]. In this setting, an accurate diagnosis can be made only after careful interpretation of all clinical and histologic features, such as the clinical history, activity of the urine sediment (red cell casts seen only in crescentic glomerulonephritis), and findings with light microscopy, immunofluorescence, and electron microscopy. (See
         <a class="medical medical_review" href="/z/d/html/3113.html" rel="external">
          "Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
         A separate issue is the possible presence of collapsing FSGS in patients in whom there is no evidence of glomerular collapse because of sampling error. Two factors would point toward the diagnosis of collapsing FSGS in such patients: a clinical history of marked proteinuria with acute kidney injury, which is not specific for collapsing FSGS but not often seen in idiopathic FSGS, and the characteristic microcystic tubular changes described above [
         <a href="#rid2">
          2,4
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">
          "Focal segmental glomerulosclerosis: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3047.html" rel="external">
          "Acute kidney injury (AKI) in minimal change disease and other forms of nephrotic syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H505254402">
         <span class="h1">
          DIAGNOSIS
         </span>
        </p>
        <p class="headingAnchor" id="H3103510402">
         <span class="h2">
          Establishing the diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of collapsing FSGS should be suspected in any patient presenting with nephrotic syndrome, especially if acute kidney injury is also present. A kidney biopsy is required to establish the diagnosis and exclude other possible causes of the nephrotic syndrome.
        </p>
        <p>
         The general evaluation of a patient with an FSGS lesion on kidney biopsy is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">
          "Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Evaluation of the patient with an FSGS lesion'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1726491016">
         <span class="h2">
          Evaluation for associated conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with the finding of collapsing FSGS on kidney biopsy, the following evaluation should be performed to evaluate for potential associated conditions (
         <a class="graphic graphic_table graphicRef72313" href="/z/d/graphic/72313.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History and physical examination, including an assessment of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Exposure to drugs and/or toxins associated with collapsing FSGS (eg, bisphosphonates, anabolic steroids, interferon) (see
         <a class="local">
          'Bisphosphonates and other drugs'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of infections (viruses [eg, HIV, parvovirus B19, SARS-COV-2, cytomegalovirus, Epstein-Barr virus (EBV)], tuberculosis, malaria, leishmaniasis) (see
         <a class="local">
          'Infections'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of another glomerular disease (eg, lupus nephritis, IgA nephropathy, diabetic kidney disease) (see
         <a class="local">
          'Autoimmune disorders'
         </a>
         above and
         <a class="local">
          'IgA nephropathy'
         </a>
         above and
         <a class="local">
          'Diabetic kidney disease'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count (CBC) with platelet count, to assess for anemia and thrombocytopenia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Examination of the peripheral blood smear for schistocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tests for HIV, parvovirus B19, SARS-COV-2, cytomegalovirus, and EBV. (See
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">
          "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8291.html" rel="external">
          "Overview of diagnostic tests for cytomegalovirus infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antinuclear antibody test. (See
         <a class="local">
          'Autoimmune disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ferritin concentration. (See
         <a class="local">
          'Hemophagocytic lymphohistiocytosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Genetic testing for APOL1 variants should be performed in all patients with collapsing FSGS in whom a positive result may influence clinical decision making (eg, prognostication, candidates for studies on the therapy of APOL1-positive patients, when deciding whether to evaluate relatives as potential donors for kidney transplantation for the patient). (See
         <a class="medical medical_review" href="/z/d/html/135174.html" rel="external">
          "Gene test interpretation:
          <i>
           APOL1
          </i>
          (chronic kidney disease gene)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H944118179">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H357469004">
         <span class="h2">
          General measures in all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         General supportive measures in all patients with collapsing FSGS include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and in selected patients, anticoagulation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be of benefit, but data and experience are limited. Other aspects of therapy include diuretics to control edema and maintenance of adequate nutrition. This approach is consistent with the 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases [
         <a href="#rid83">
          83
         </a>
         ]. These issues are discussed in greater detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dietary sodium and protein restriction (see
         <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">
          "Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Salt intake'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7178.html" rel="external">
          "Dietary recommendations for patients with nondialysis chronic kidney disease", section on 'Protein intake'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antihypertensive therapy (see
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Renin-angiotensin system inhibition (see
         <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">
          "Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults", section on 'Renin-angiotensin system inhibitors'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SGLT2 inhibitors (see
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults", section on 'Patients with proteinuria'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lipid lowering (see
         <a class="medical medical_review" href="/z/d/html/3114.html" rel="external">
          "Lipid abnormalities in nephrotic syndrome", section on 'Management'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticoagulation (see
         <a class="medical medical_review" href="/z/d/html/3043.html" rel="external">
          "Hypercoagulability in nephrotic syndrome", section on 'Patients with other causes of nephrotic syndrome'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of edema (see
         <a class="medical medical_review" href="/z/d/html/7172.html" rel="external">
          "Overview of the management of chronic kidney disease in adults", section on 'Volume overload'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1276446061">
         <span class="h2">
          Patients with idiopathic collapsing FSGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no clinical trials to guide the optimal therapy of idiopathic collapsing FSGS, and our approach is based primarily upon our clinical experience and data from retrospective studies.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4107745278">
         <span class="h3">
          Initial immunosuppressive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, we treat most patients with idiopathic collapsing FSGS and nephrotic-range proteinuria with immunosuppressive therapy. Exceptions include patients who have contraindications to immunosuppression (eg, active infection) and those with more advanced kidney disease (ie, histologic evidence of extensive glomerulosclerosis and interstitial fibrosis on kidney biopsy) who are unlikely to respond to therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest oral glucocorticoids as initial therapy. We typically give oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         100 to 120 mg every other day for the first two months, then subsequently taper the dose by 20 mg every two weeks until 40 mg every other day is reached, for a total of six months of therapy, at which time we discontinue the prednisone without further taper. Some clinicians prefer to start with daily dosing of glucocorticoids and then change to alternate-day therapy. Glucocorticoids should be used with caution, if at all, in patients at high risk for infection or in patients with diabetes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some but not all UpToDate contributors to this topic administer antimicrobial prophylaxis again
         <em>
          st Pneumocystis
         </em>
         pneumonia (PCP) for the duration of glucocorticoid treatment. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who present with large amounts of proteinuria (&gt;10 g/day), severe hypoalbuminemia (serum albumin of &lt;2 g/dL),
         <strong>
          and
         </strong>
         preserved kidney function (estimated glomerular filtration rate [eGFR] ≥45 mL/min/1.73 m
         <sup>
          2
         </sup>
         ), we prefer to add a calcineurin inhibitor (CNI;
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ) for the duration of glucocorticoid therapy to accelerate reversal of the proteinuria and hypoalbuminemia. The dosing of CNIs in patients with idiopathic collapsing FSGS is the same as for patients with primary (idiopathic) FSGS who are receiving CNIs as initial therapy. (See
         <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">
          "Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Calcineurin inhibitors as alternative initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         There are no high-quality studies that have examined the efficacy of immunosuppressive therapy for idiopathic collapsing FSGS, and data primarily come from small retrospective studies [
         <a href="#rid32">
          32,76,77,79
         </a>
         ]. Most, but not all, of these studies have shown a frequently poor response to immunosuppressive therapy. However, the largest series of 61 patients, 37 of whom were treated with immunosuppressive agents, found that those treated with immunosuppression had higher rates of complete or partial remission (70 versus 40 percent) and lower rates of end-stage kidney disease (35 versus 74 percent) compared with those who were treated with supportive therapy alone [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         In most cases, glucocorticoids have been used, alone or in combination with a CNI (mostly
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ) or a cytotoxic agent (such as
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ). However, no prospective studies have directly compared the efficacy of different immunosuppressive regimens. Our practice is to use glucocorticoids as initial therapy in most patients. We do not use cytotoxic agents, such as cyclophosphamide or
         <a class="drug drug_general" data-topicid="9240" href="/z/d/drug information/9240.html" rel="external">
          chlorambucil
         </a>
         , given their poor efficacy and significant side effect profile [
         <a href="#rid32">
          32,76,77
         </a>
         ].
        </p>
        <p>
         Patients with severe nephrotic syndrome (eg, proteinuria &gt;10 g/day and serum albumin &lt;2 g/dL) generally have a poor prognosis, and early, more intensive therapy (eg, glucocorticoids plus a CNI) may be beneficial if kidney function is reasonably well preserved. There are no data to support this approach, and combination treatment with glucocorticoids and other immunosuppressive agents has not been proven to be superior to glucocorticoids alone. In a retrospective analysis of 275 patients who underwent immunosuppressive treatment for biopsy-proven primary FSGS (15 percent of whom had collapsing FSGS), there was no difference in the adjusted risk of end-stage kidney disease between patients treated with CNIs (with or without glucocorticoids) compared with those treated with glucocorticoids alone [
         <a href="#rid84">
          84
         </a>
         ]. Nevertheless, a trial of more intensive immunosuppression is reasonable in patients with severe nephrotic syndrome given their otherwise poor prognosis.
        </p>
        <p class="headingAnchor" id="H2255623831">
         <span class="h3">
          Monitoring the response to therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no specific guidelines for monitoring the response to therapy. In patients receiving immunosuppressive therapy, we measure routine blood chemistries, including a plasma creatinine concentration for estimation of GFR, serum albumin concentration, and urine protein-to-creatinine ratio, every two to four weeks for the first two months and, if stable, monthly thereafter.
        </p>
        <p>
         In patients receiving a CNI, we monitor whole blood trough concentrations on a monthly basis, aiming for
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         trough levels of 125 to 225 ng/mL or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         trough levels of 5 to 10 ng/mL, although the lowest effective dose of CNI should be used to limit nephrotoxicity.
        </p>
        <p>
         The response to therapy is assessed in terms of degree of reduction in proteinuria, using definitions that are the same as those used for patients with primary FSGS. (See
         <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">
          "Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Monitoring the response to therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1585724651">
         <span class="h3">
          Resistant disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optimal treatment for patients who do not respond to initial therapy with glucocorticoids with or without a CNI is not known. Collapsing FSGS often progresses quickly among patients who are resistant to initial immunosuppressive therapy, and the prognosis of such patients is typically poor. Our approach in patients with resistant disease is based upon personal experience and limited data from case reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who do not respond to initial therapy with glucocorticoids alone and who have an eGFR ≥30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we discontinue glucocorticoids and treat with a CNI (
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         or
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ). Some experts switch to a CNI prior to the completion of six months of glucocorticoid monotherapy if the patient does not show any signs of response after 12 to 16 weeks. Other experts would treat with a CNI and continue low-dose glucocorticoids (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         5 to 10 mg/day). The dosing and duration of CNIs in patients with collapsing FSGS are the same as for patients receiving these drugs as initial therapy for primary FSGS. (See
         <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">
          "Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Calcineurin inhibitors as alternative initial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients who have an eGFR &lt;30 mL/min/1.73 m
         <sup>
          2
         </sup>
         , we avoid using CNIs given the additional risk of nephrotoxicity in these patients. In such patients,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (1 g initially followed 14 days later by another 1 g dose) is an alternative option, although the disease is often too advanced to consider further immunosuppression. Although there are no large studies to support this approach, case reports have described the successful use of rituximab in patients with resistant disease [
         <a href="#rid85">
          85-87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who do not respond to initial therapy with glucocorticoids plus a CNI, we discontinue these agents, since further treatment is unlikely to be of additional benefit. Some contributors to this topic would suggest a trial of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (1 g initially followed 14 days later by another 1 g dose) based on limited data from case reports suggesting possible benefit [
         <a href="#rid85">
          85-87
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3749357530">
         <span class="h3">
          Relapsing disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disease relapse (ie, a return of proteinuria to ≥3.5 g/day) following a good initial response to immunosuppressive therapy is uncommon among minimal change disease/patients with idiopathic collapsing FSGS. Treatment in this rare scenario would be similar to the therapy that achieved the initial remission. (See
         <a class="local">
          'Initial immunosuppressive therapy'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H746932643">
         <span class="h2">
          Patients with associated conditions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the treatment of collapsing FSGS with associated conditions is directed at the underlying condition responsible for the collapsing FSGS. Immunosuppressive therapy is
         <strong>
          not
         </strong>
         typically recommended, except in a few special circumstances, as discussed below. In addition, all patients with collapsing FSGS associated with secondary causes should receive general measures, such as blood pressure control, minimization of proteinuria with angiotensin inhibition, and treatment of dyslipidemia. (See
         <a class="local">
          'General measures in all patients'
         </a>
         above.)
        </p>
        <p>
         It should be recognized that the high-risk
         <em>
          APOL1
         </em>
         genotypes are susceptibility alleles, rather than secondary causes, and patients with these genotypes may still respond favorably to immunosuppression. (See
         <a class="local">
          'APOL1 high-risk alleles'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Collapsing FSGS associated with infections
         </strong>
         – In patients with collapsing FSGS associated with infections (eg, parvovirus B19, cytomegalovirus, hepatitis C virus, hepatitis B virus, malaria, or tuberculosis) (see
         <a class="local">
          'Infections'
         </a>
         above), treatment of the underlying infection may improve kidney outcomes. As an example, in two case reports of collapsing FSGS associated with acute cytomegalovirus infection, treatment with antiviral agents (
         <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">
          ganciclovir
         </a>
         ) and prolonged oral glucocorticoids resulted in an improvement in kidney function [
         <a href="#rid88">
          88,89
         </a>
         ]. The role of glucocorticoids or other immunomodulatory agents in patients receiving anti-infective therapy is unclear. The risk of exacerbating the active infection must be recognized if glucocorticoids are being considered, and in most cases, this risk is likely to outweigh the potential benefit. The treatment of individual infections associated with collapsing FSGS is discussed separately:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8330.html" rel="external">
          "Treatment and prevention of parvovirus B19 infection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8289.html" rel="external">
          "Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent adults", section on 'Therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/488.html" rel="external">
          "Antituberculous drugs: An overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Collapsing FSGS associated with drugs
         </strong>
         – In patients with collapsing FSGS associated with drugs (see
         <a class="local">
          'Bisphosphonates and other drugs'
         </a>
         above), the primary approach to treatment is discontinuation of the offending agent. We do not routinely treat such patients with immunosuppressive therapy; however, the addition of glucocorticoids and/or a CNI may be considered depending upon the rapidity of deterioration in kidney function and the response to stopping the medication. Outcomes are variable, but both complete and partial remissions have been described after discontinuation of bisphosphonates without immunosuppression. The additional use of glucocorticoids has been reported, but it is unclear if the improvement in these cases was related to the immunosuppression or merely discontinuation of the drug [
         <a href="#rid51">
          51,52,90-92
         </a>
         ]. Improvement after discontinuation of anabolic steroids has also been described [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Collapsing FSGS associated with other disorders
         </strong>
         – Collapsing FSGS in patients with systemic lupus erythematosus typically presents in the setting of a lupus flare and may occur with or without the presence of concurrent lupus nephritis on kidney biopsy [
         <a href="#rid55">
          55-59
         </a>
         ]. There are no clinical trials to guide therapy in this rare condition, but patients are often treated with immunosuppression similar to that used for class IV lupus nephritis. One study suggested a better response to therapy in patients who had concurrent lupus nephritis compared with those who only had collapsing FSGS on biopsy [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3059.html" rel="external">
          "Lupus nephritis: Initial and subsequent therapy for focal or diffuse lupus nephritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When collapsing FSGS occurs in the setting of diabetic kidney disease or IgA nephropathy, it may be secondary to ischemia or vascular disease. Immunosuppressive therapy with glucocorticoids as discussed above (see
         <a class="local">
          'Initial immunosuppressive therapy'
         </a>
         above) may be reasonable in such patients who present with a more acute, severely nephrotic presentation. The use of glucocorticoids and other immunosuppressive medications must be weighed against the risk of infections and other complications.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2432535496">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, the prognosis of idiopathic collapsing FSGS not associated with HIV infection is poor [
         <a href="#rid4">
          4,76-79
         </a>
         ]. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One retrospective study compared kidney outcomes between 61 patients with collapsing FSGS and 126 patients with noncollapsing FSGS [
         <a href="#rid79">
          79
         </a>
         ]. At baseline, patients with collapsing FSGS had higher levels of proteinuria (12 versus 4 g/day) and lower estimated glomerular filtration rate (eGFR; 48 versus 60 mL/min/1.73 m
         <sup>
          2
         </sup>
         ). At a median of 69 months, patients with collapsing FSGS were more likely to have end-stage kidney disease than those with noncollapsing FSGS (48 versus 26 percent). However, it should be noted in the 37 patients treated with immunosuppression, 70 percent achieved a complete or partial remission, suggesting that there may be a benefit to early immunosuppressive therapy. (See
         <a class="local">
          'Initial immunosuppressive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another large series compared 43 patients with collapsing FSGS with 50 matched controls with idiopathic FSGS [
         <a href="#rid77">
          77
         </a>
         ]. The mean time from biopsy to end-stage kidney disease with collapsing FSGS was much shorter than in the patients with idiopathic FSGS (13 versus 63 months). However, most patients in this series had advanced kidney function impairment and marked interstitial fibrosis on kidney biopsy at the time of diagnosis.
        </p>
        <p>
        </p>
        <p>
         Similar findings were noted in two other retrospective series. Patients with collapsing FSGS were more likely to be on dialysis within 15 months (5 of 14 compared with none of 25 with noncollapsing FSGS) [
         <a href="#rid76">
          76
         </a>
         ] and at five years (40 versus 0 percent) [
         <a href="#rid78">
          78
         </a>
         ]. The first prospective study of different FSGS variants confirmed the poor prognosis for collapsing FSGS [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
         The prognosis for collapsing FSGS associated with other diseases is more variable. The numbers of patients with collapsing FSGS associated with entities such as systemic lupus erythematosus or bisphosphonates are too small to draw firm conclusions about whether the course of such patients differs significantly from that of patients with idiopathic collapsing FSGS. In general, collapsing FSGS associated with SLE has a more rapidly progressive course, whereas some medication-induced (eg,
         <a class="drug drug_general" data-topicid="9736" href="/z/d/drug information/9736.html" rel="external">
          pamidronate
         </a>
         ) or familial forms of collapsing FSGS may have a better prognosis. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1527830248">
         <span class="h1">
          TRANSPLANTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplantation has been performed in patients with idiopathic collapsing FSGS. Recurrent disease can occur, supporting the presence of a pathogenic circulating factor, with a recurrence rate similar to that of other patterns of FSGS [
         <a href="#rid4">
          4,34,35
         </a>
         ]. De novo collapsing FSGS in the kidney allograft has also been described and may occur in the setting of inflammation (acute rejection or viral infections [especially cytomegalovirus]), or secondary to glomerular ischemia from acute vascular occlusion (due to thrombotic microangiopathy [TMA], atheroembolism, or cortical necrosis) [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7342.html" rel="external">
          "Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3836245914">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">
          "Society guideline links: Glomerular disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H504400161">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Collapsing focal segmental glomerulosclerosis (collapsing FSGS; also known as collapsing glomerulopathy) is a cause of the nephrotic syndrome that is characterized histologically by segmentally or globally collapsed glomerular capillaries and severe tubulointerstitial disease. In the past, collapsing FSGS was most often seen in association with HIV infection but is increasingly recognized in patients without HIV. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis
         </strong>
         – The underlying pathogenic event appears to be a severe insult to the integrity and biology of the glomerular visceral epithelial (podocytes) and parietal epithelial cells. This is accompanied by a profound loss of function of the glomerular filtration barrier. There may be a genetic predisposition toward collapsing FSGS. Black patients with risk polymorphisms in the
         <em>
          APOL1
         </em>
         gene are at increased susceptibility to develop collapsing glomerulopathy. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – The majority of cases of collapsing FSGS are idiopathic. However, collapsing FSGS has been reported to occur in association with a growing list of disorders (
         <a class="graphic graphic_table graphicRef72313" href="/z/d/graphic/72313.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Patients with idiopathic collapsing FSGS present with a similar clinical picture as those with HIV-associated collapsing FSGS. This can include a preceding or ongoing febrile illness, severe nephrotic syndrome, kidney function impairment at presentation, and rapid progression to end-stage kidney disease. On urinalysis, the nephrotic sediment is associated with heavy proteinuria, lipiduria, and occasionally large granular casts. Compared with typical FSGS, collapsing FSGS presents with more severe kidney involvement, including higher levels of proteinuria (commonly over 10 g/day) and more severe kidney dysfunction. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of non-HIV collapsing FSGS should be suspected in any patient presenting with nephrotic syndrome, especially if acute kidney injury is also present. A kidney biopsy is required to confirm the diagnosis and to exclude other possible causes of the nephrotic syndrome. In patients with the finding of collapsing FSGS on kidney biopsy, an evaluation should be performed to exclude potential secondary causes. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Supportive measures in all patients
         </strong>
         – General supportive measures in all patients with collapsing FSGS include dietary sodium and protein restriction, blood pressure control, minimization of proteinuria with renin-angiotensin system inhibition, treatment of dyslipidemia, and in selected patients, anticoagulation. Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be of benefit, but data and experience are limited. (See
         <a class="local">
          'General measures in all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Idiopathic collapsing FSGS
         </strong>
         – There are no high-quality studies to guide the optimal treatment of idiopathic collapsing FSGS, and our approach is based upon the clinical expertise of the authors and editors:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with idiopathic collapsing FSGS who do not have a contraindication to immunosuppression, we suggest initial therapy with glucocorticoids plus supportive measures rather than supportive measures alone or combined with alternative immunosuppressive therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with large amounts of proteinuria (&gt;10 g/day), severe hypoalbuminemia (serum albumin of &lt;2 g/dL), and preserved kidney function (estimated glomerular filtration rate [eGFR] ≥45 mL/min), we prefer to add a calcineurin inhibitor to the glucocorticoid regimen to accelerate reversal of the hypoalbuminemia and proteinuria. Although there are no data to support this approach, a trial of more intensive immunosuppression is reasonable in patients with severe nephrotic syndrome given their otherwise poor prognosis. (See
         <a class="local">
          'Initial immunosuppressive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients with associated conditions
         </strong>
         – The treatment of non-HIV collapsing FSGS with associated conditions is directed at the underlying condition responsible for the collapsing FSGS. Immunosuppressive therapy is not typically recommended, except in a few special circumstances, as discussed above. (See
         <a class="local">
          'Patients with associated conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3527113910">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Peter J Nelson, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cutrim ÉMM, Neves PDMM, Campos MAG, et al. Collapsing Glomerulopathy: A Review by the Collapsing Brazilian Consortium. Front Med (Lausanne) 2022; 9:846173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol 2003; 23:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholas Cossey L, Larsen CP, Liapis H. Collapsing glomerulopathy: a 30-year perspective and single, large center experience. Clin Kidney J 2017; 10:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albaqumi M, Soos TJ, Barisoni L, Nelson PJ. Collapsing glomerulopathy. J Am Soc Nephrol 2006; 17:2854.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shankland SJ, Smeets B, Pippin JW, Moeller MJ. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 2014; 10:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp JB, Winkler CA, Zhao X, et al. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol 2015; 26:1443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013; 24:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols B, Jog P, Lee JH, et al. Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1. Kidney Int 2015; 87:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen CP, Beggs ML, Walker PD, et al. Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy. Am J Kidney Dis 2014; 64:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah PB, Cooper JE, Lucia MS, et al. APOL1 Polymorphisms in a Deceased Donor and Early Presentation of Collapsing Glomerulopathy and Focal Segmental Glomerulosclerosis in Two Recipients. Am J Transplant 2016; 16:1923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larsen CP, Bourne TD, Wilson JD, et al. Collapsing Glomerulopathy in a Patient With COVID-19. Kidney Int Rep 2020; 5:935.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kudose S, Santoriello D, Bomback AS, et al. Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies. J Am Soc Nephrol 2021; 32:2958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr SH, Kopp JB. COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity. Kidney Int Rep 2020; 5:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peleg Y, Kudose S, D'Agati V, et al. Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection. Kidney Int Rep 2020; 5:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu J, Raman A, Coffey NJ, et al. The key role of NLRP3 and STING in APOL1-associated podocytopathy. J Clin Invest 2021; 131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman DJ, Pollak MR. APOL1 Nephropathy: From Genetics to Clinical Applications. Clin J Am Soc Nephrol 2021; 16:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daneshpajouhnejad P, Kopp JB, Winkler CA, Rosenberg AZ. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning. Nat Rev Nephrol 2022; 18:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams WW, Ingelfinger JR. Inhibiting APOL1 to Treat Kidney Disease. N Engl J Med 2023; 388:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, et al. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007; 18:2773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gasser DL, Winkler CA, Peng M, et al. Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q10. Am J Physiol Renal Physiol 2013; 305:F1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Badhwar A, Berkovic SF, Dowling JP, et al. Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder. Brain 2004; 127:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagano C, Hara S, Yoshikawa N, et al. Clinical, Pathological, and Genetic Characteristics in Patients with Focal Segmental Glomerulosclerosis. Kidney360 2022; 3:1384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarin S, Javidan A, Boivin F, et al. Insights into the renal pathogenesis in Schimke immuno-osseous dysplasia: A renal histological characterization and expression analysis. J Histochem Cytochem 2015; 63:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal AK, Zhou XJ, Hall RK, et al. Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency. J Investig Med 2006; 54:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jinks RN, Puffenberger EG, Baple E, et al. Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73. Brain 2015; 138:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Younsi M, Kraoua L, Meddeb R, et al. WDR73-related galloway mowat syndrome with collapsing glomerulopathy. Eur J Med Genet 2019; 62:103550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liakopoulos V, Huerta A, Cohen S, et al. Familial collapsing focal segmental glomerulosclerosis. Clin Nephrol 2011; 75:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palma Diaz MF, Pichler RH, Nicosia RF, et al. Collapsing glomerulopathy associated with natural killer cell leukemia: a case report and review of the literature. Am J Kidney Dis 2011; 58:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abid Q, Best Rocha A, Larsen CP, et al. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI). Am J Kidney Dis 2020; 75:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurinavicius A, Hurwitz S, Rennke HG. Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study. Kidney Int 1999; 56:2203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avila-Casado Mdel C, Perez-Torres I, Auron A, et al. Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. Kidney Int 2004; 66:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stokes MB, Davis CL, Alpers CE. Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations. Am J Kidney Dis 1999; 33:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toth CM, Pascual M, Williams WW Jr, et al. Recurrent collapsing glomerulopathy. Transplantation 1998; 65:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moudgil A, Nast CC, Bagga A, et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int 2001; 59:2126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coventry S, Shoemaker LR. Collapsing glomerulopathy in a 16-year-old girl with pulmonary tuberculosis: the role of systemic inflammatory mediators. Pediatr Dev Pathol 2004; 7:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomlinson L, Boriskin Y, McPhee I, et al. Acute cytomegalovirus infection complicated by collapsing glomerulopathy. Nephrol Dial Transplant 2003; 18:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leblond V, Beaufils H, Ginsburg C, et al. Collapsing focal segmental glomerulosclerosis associated with visceral leishmaniasis. Nephrol Dial Transplant 1994; 9:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beltrame A, Arzese A, Camporese A, et al. Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B. J Travel Med 2008; 15:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muehlig AK, Gies S, Huber TB, Braun F. Collapsing Focal Segmental Glomerulosclerosis in Viral Infections. Front Immunol 2021; 12:800074.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype. J Am Soc Nephrol 2020; 31:1688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shetty AA, Tawhari I, Safar-Boueri L, et al. COVID-19-Associated Glomerular Disease. J Am Soc Nephrol 2021; 32:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velez JCQ, Caza T, Larsen CP. COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19. Nat Rev Nephrol 2020; 16:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giannini G, Carlos Q Velez J, May RM, et al. Renal Prognosis of COVID-19 Associated Nephropathy. Kidney Int Rep 2022; 7:2722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 2001; 12:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz GS, Fine PL, D'agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis 2002; 39:1118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lockridge L, Papac RJ, Perazella MA. Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis. Am J Kidney Dis 2002; 40:E2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ten Dam MA, Hilbrands LB, Wetzels JF. Nephrotic syndrome induced by pamidronate. Med Oncol 2011; 28:1196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual J, Torrealba J, Myers J, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int 2007; 18:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Herlitz LC, Markowitz GS, Farris AB, et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010; 21:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz GS, Nasr SH, Stokes MB, D'Agati VD. Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvatore SP, Barisoni LM, Herzenberg AM, et al. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol 2012; 7:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amoura Z, Georgin-Lavialle S, Haroche J, et al. Collapsing glomerulopathy in systemic autoimmune disorders: a case occurring in the course of full blown systemic lupus erythematosus. Ann Rheum Dis 2006; 65:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marques LP, Pacheco GG, Rioja LS, et al. Can systemic lupus erythematosus be the cause of collapsing glomerulopathy? Lupus 2005; 14:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melo NC, Malheiros DM, Barros RT, Woronik V. Collapsing glomerulopathy associated with proliferative lupus nephritis: reversible acute kidney injury. Lupus 2011; 20:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Sharma A, Bhowmik D, et al. Collapsing glomerulopathy occurring in HIV-negative patients with systemic lupus erythematosus: report of three cases and brief review of the literature. Lupus 2011; 20:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar S, Sheaff M, Yaqoob M. Collapsing glomerulopathy in adult still's disease. Am J Kidney Dis 2004; 43:e4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arulkumaran N, Reitbock P, Halliday K, et al. Adult-onset Still's disease associated with collapsing glomerulopathy. NDT Plus 2010; 3:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atari M, Ambruzs JM, Saqqa O, Simon EE. Collapsing glomerulopathy in a patient with mixed connective tissue disease. Am J Med Sci 2022; 364:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Granata A, Floccari F. Behcet's disease and focal segmental glomerulosclerosis: an unusual association. Rheumatol Int 2012; 32:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El Karoui K, Hill GS, Karras A, et al. Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int 2011; 79:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook HT. Focal segmental glomerulosclerosis in IgA nephropathy: a result of primary podocyte injury? Kidney Int 2011; 79:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvatore SP, Reddi AS, Chandran CB, et al. Collapsing glomerulopathy superimposed on diabetic nephropathy: insights into etiology of an under-recognized, severe pattern of glomerular injury. Nephrol Dial Transplant 2014; 29:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buob D, Decambron M, Gnemmi V, et al. Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney. Kidney Int 2016; 90:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santoriello D, Husain SA, De Serres SA, et al. Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts. Kidney Int 2018; 94:1189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenberg A, Bastacky SI, Iqbal A, et al. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am J Kidney Dis 1997; 29:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr SH, Markowitz GS, Sentman RL, D'Agati VD. Sickle cell disease, nephrotic syndrome, and renal failure. Kidney Int 2006; 69:1276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Canaud G, Bruneval P, Noël LH, et al. Glomerular collapse associated with subtotal renal infarction in kidney transplant recipients with multiple renal arteries. Am J Kidney Dis 2010; 55:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kukull B, Avasare RS, Smith KD, et al. Collapsing glomerulopathy in older adults. Mod Pathol 2019; 32:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thaunat O, Delahousse M, Fakhouri F, et al. Nephrotic syndrome associated with hemophagocytic syndrome. Kidney Int 2006; 69:1892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niang A, Niang SE, Ka el HF, et al. Collapsing glomerulopathy and haemophagocytic syndrome related to malaria: a case report. Nephrol Dial Transplant 2008; 23:3359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiss MA, Daquioag E, Margolin EG, Pollak VE. Nephrotic syndrome, progressive irreversible renal failure, and glomerular "collapse": a new clinicopathologic entity? Am J Kidney Dis 1986; 7:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Detwiler RK, Falk RJ, Hogan SL, Jennette JC. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int 1994; 45:1416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valeri A, Barisoni L, Appel GB, et al. Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study. Kidney Int 1996; 50:1734.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grcevska L, Polenakovik M. Collapsing glomerulopathy: clinical characteristics and follow-up. Am J Kidney Dis 1999; 33:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurin LP, Gasim AM, Derebail VK, et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol 2016; 11:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Agati VD, Alster JM, Jennette JC, et al. Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol 2013; 8:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Agati V. Pathologic classification of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorner PS, Ho M, Eremina V, et al. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008; 19:495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021; 100:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laurin LP, Gasim AM, Poulton CJ, et al. Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS. Clin J Am Soc Nephrol 2016; 11:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramachandran R, Rajakumar V, Duseja R, et al. Successful treatment of adult-onset collapsing focal segmental glomerulosclerosis with rituximab. Clin Kidney J 2013; 6:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaito H, Kamei K, Kikuchi E, et al. Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin. Pediatr Nephrol 2010; 25:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ochi A, Takei T, Nakayama K, et al. Rituximab treatment for adult patients with focal segmental glomerulosclerosis. Intern Med 2012; 51:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grover V, Gaiki MR, DeVita MV, Schwimmer JA. Cytomegalovirus-induced collapsing focal segmental glomerulosclerosis. Clin Kidney J 2013; 6:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Presne C, Cordonnier C, Makdassi R, et al. [Collapsing glomerulopathy and cytomegalovirus, what are the links?]. Presse Med 2000; 29:1815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stratton JD, Warwicker P. Relapse of nephrotic syndrome triggered by biphosphonates. Nephrol Dial Transplant 2002; 17:1856.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shreedhara M, Fenves AZ, Benavides D, Stone MJ. Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent) 2007; 20:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prikis M, Gibson PC, Weise WJ. Alendronate-associated focal segmental glomerulosclerosis. NDT Plus 2009; 2:91.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3080 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35308512" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Collapsing Glomerulopathy: A Review by the Collapsing Brazilian Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12704581" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28852479" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Collapsing glomerulopathy: a 30-year perspective and single, large center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16914539" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24468766" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The emergence of the glomerular parietal epithelial cell.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647424" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Association of trypanolytic ApoL1 variants with kidney disease in African Americans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21997394" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25573908" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23520206" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25100047" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24731740" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26849829" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : APOL1 Polymorphisms in a Deceased Donor and Early Presentation of Collapsing Glomerulopathy and Focal Segmental Glomerulosclerosis in Two Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32292867" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Collapsing Glomerulopathy in a Patient With COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34670811" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Longitudinal Outcomes of COVID-19-Associated Collapsing Glomerulopathy and Other Podocytopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32368701" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : COVID-19-Associated Collapsing Glomerulopathy: An Emerging Entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32346659" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acute Kidney Injury Due to Collapsing Glomerulopathy Following COVID-19 Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34651582" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The key role of NLRP3 and STING in APOL1-associated podocytopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32616495" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : APOL1 Nephropathy: From Genetics to Clinical Applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35217848" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36920762" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Inhibiting APOL1 to Treat Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17855635" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23926186" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Focal segmental glomerulosclerosis is associated with a PDSS2 haplotype and, independently, with a decreased content of coenzyme Q10.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15364701" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Action myoclonus-renal failure syndrome: characterization of a unique cerebro-renal disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36176665" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical, Pathological, and Genetic Characteristics in Patients with Focal Segmental Glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25319549" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Insights into the renal pathogenesis in Schimke immuno-osseous dysplasia: A renal histological characterization and expression analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17152860" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Focal segmental glomerulosclerosis in patients with mandibuloacral dysplasia owing to ZMPSTE24 deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26070982" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Recessive nephrocerebellar syndrome on the Galloway-Mowat syndrome spectrum is caused by homozygous protein-truncating mutations of WDR73.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30315938" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : WDR73-related galloway mowat syndrome with collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21426891" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Familial collapsing focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21908087" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Collapsing glomerulopathy associated with natural killer cell leukemia: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31601430" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10594796" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Collapsing glomerulopathy in HIV and non-HIV patients: a clinicopathological and follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15200420" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Proteinuria in rats induced by serum from patients with collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10196006" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Collapsing glomerulopathy in renal allografts: a morphological pattern with diverse clinicopathologic associations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9565112" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Recurrent collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11380814" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15022071" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Collapsing glomerulopathy in a 16-year-old girl with pulmonary tuberculosis: the role of systemic inflammatory mediators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12480980" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Acute cytomegalovirus infection complicated by collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7816308" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Collapsing focal segmental glomerulosclerosis associated with visceral leishmaniasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19006511" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Acute renal failure due to visceral leishmaniasis by Leishmania infantum successfully treated with a single high dose of liposomal amphotericin B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35095882" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Collapsing Focal Segmental Glomerulosclerosis in Viral Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32561682" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : AKI and Collapsing Glomerulopathy Associated with COVID-19 and APOL1 High-Risk Genotype.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33214201" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : COVID-19-Associated Glomerular Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32753739" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : COVAN is the new HIVAN: the re-emergence of collapsing glomerulopathy with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36277848" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Renal Prognosis of COVID-19 Associated Nephropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18685574" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Bisphosphonate nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11373339" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11979358" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Nephrotic syndrome after treatment with pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14717935" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Podocyte injury associated glomerulopathies induced by pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12087588" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Pamidronate-associated nephrotoxicity in a patient with Langerhans's histiocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20865462" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Nephrotic syndrome induced by pamidronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17404782" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19917783" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Development of focal segmental glomerulosclerosis after anabolic steroid abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203164" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22461531" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16410539" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Collapsing glomerulopathy in systemic autoimmune disorders: a case occurring in the course of full blown systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16302682" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Can systemic lupus erythematosus be the cause of collapsing glomerulopathy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21078765" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Collapsing glomerulopathy associated with proliferative lupus nephritis: reversible acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21339242" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Collapsing glomerulopathy occurring in HIV-negative patients with systemic lupus erythematosus: report of three cases and brief review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15112192" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Collapsing glomerulopathy in adult still's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25949406" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Adult-onset Still's disease associated with collapsing glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35430254" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Collapsing glomerulopathy in a patient with mixed connective tissue disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21833522" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Behcet's disease and focal segmental glomerulosclerosis: an unusual association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21178978" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21358653" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Focal segmental glomerulosclerosis in IgA nephropathy: a result of primary podocyte injury?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24081860" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Collapsing glomerulopathy superimposed on diabetic nephropathy: insights into etiology of an under-recognized, severe pattern of glomerular injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27650730" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Collapsing glomerulopathy is common in the setting of thrombotic microangiopathy of the native kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30287079" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9041208" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16482096" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Sickle cell disease, nephrotic syndrome, and renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19800721" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Glomerular collapse associated with subtotal renal infarction in kidney transplant recipients with multiple renal arteries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30327500" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Collapsing glomerulopathy in older adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16557222" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Nephrotic syndrome associated with hemophagocytic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18676345" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Collapsing glomerulopathy and haemophagocytic syndrome related to malaria: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3510532" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Nephrotic syndrome, progressive irreversible renal failure, and glomerular "collapse": a new clinicopathologic entity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8072254" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8914044" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Idiopathic collapsing focal segmental glomerulosclerosis: a clinicopathologic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10196005" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Collapsing glomerulopathy: clinical characteristics and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27445167" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23220425" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Association of histologic variants in FSGS clinical trial with presenting features and outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12704572" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Pathologic classification of focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18199804" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Podocytes contribute to the formation of glomerular crescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34556256" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26912551" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Treatment with Glucocorticoids or Calcineurin Inhibitors in Primary FSGS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26120443" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Successful treatment of adult-onset collapsing focal segmental glomerulosclerosis with rituximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20033219" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Successful treatment of collapsing focal segmental glomerulosclerosis with a combination of rituximab, steroids and ciclosporin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22466834" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Rituximab treatment for adult patients with focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27818753" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Cytomegalovirus-induced collapsing focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11109435" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : [Collapsing glomerulopathy and cytomegalovirus, what are the links?].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12271004" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Relapse of nephrotic syndrome triggered by biphosphonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17637879" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Reversibility of pamidronate-associated glomerulosclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25949300" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Alendronate-associated focal segmental glomerulosclerosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
